Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $77.46 in the prior trading day, Conmed Corp. (NYSE: CNMD) closed at $72.76, down -6.07%. In other words, the price has decreased by -$6.07 from its previous closing price. On the day, 0.92 million shares were traded. CNMD stock price reached its highest trading level at $77.73 during the session, while it also had its lowest trading level at $72.66.
Ratios:
Our goal is to gain a better understanding of CNMD by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 92.19 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 21.07. For the most recent quarter (mrq), Quick Ratio is recorded 0.96 and its Current Ratio is at 1.98. In the meantime, Its Debt-to-Equity ratio is 1.19 whereas as Long-Term Debt/Eq ratio is at 1.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on February 01, 2024, Reiterated its Buy rating but revised its target price to $129 from $119 previously.
On May 22, 2023, CL King started tracking the stock assigning a Buy rating and target price of $140.
KeyBanc Capital Markets Upgraded its Sector Weight to Overweight on March 27, 2023, while the target price for the stock was maintained at $124.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 04 ’23 when Peters Stanley W III sold 2,300 shares for $109.93 per share. The transaction valued at 252,833 led to the insider holds 63 shares of the business.
Peters Stanley W III sold 1,200 shares of CNMD for $122,874 on Nov 07 ’23. The President AS and AET now owns 63 shares after completing the transaction at $102.39 per share. On Sep 13 ’23, another insider, Peters Stanley W III, who serves as the President AS and AET of the company, sold 2,000 shares for $107.31 each. As a result, the insider received 214,629 and left with 63 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CNMD now has a Market Capitalization of 2240367872 and an Enterprise Value of 3206552064. As of this moment, Conmed’s Price-to-Earnings (P/E) ratio for their current fiscal year is 35.67, and their Forward P/E ratio for the next fiscal year is 12.95. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.40. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.81 while its Price-to-Book (P/B) ratio in mrq is 2.68. Its current Enterprise Value per Revenue stands at 2.576 whereas that against EBITDA is 16.218.
Stock Price History:
Over the past 52 weeks, CNMD has reached a high of $138.47, while it has fallen to a 52-week low of $73.88. The 50-Day Moving Average of the stock is -9.60%, while the 200-Day Moving Average is calculated to be -28.17%.
Shares Statistics:
The stock has traded on average 580.84K shares per day over the past 3-months and 457640 shares per day over the last 10 days, according to various share statistics. A total of 30.77M shares are outstanding, with a floating share count of 30.55M. Insiders hold about 0.79% of the company’s shares, while institutions hold 116.86% stake in the company. Shares short for CNMD as of 1711584000 were 4065281 with a Short Ratio of 7.00, compared to 1709164800 on 3955370. Therefore, it implies a Short% of Shares Outstanding of 4065281 and a Short% of Float of 18.32.
Dividends & Splits
In the trailing 12 months, CNMD’s forward annual dividend rate was 0.8, compared to 0.80 this year. The stock’s 5-year Average Dividend Yield is 0.79.
Earnings Estimates
Conmed Corp. (CNMD) is presently subject to a detailed evaluation by Mind Medicine (MindMed) Inc. analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $5.44, with high estimates of $72.76 and low estimates of $17.45.
Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Healthcare.
